Skip to main content
PRGO
NYSE Life Sciences

Shareholders Approve New Long-Term Incentive Plan with Significant Potential Dilution

Analysis by Arik Shkolnikov
Sentiment info
Neutral
Importance info
7
Price
$11.64
Mkt Cap
$1.602B
52W Low
$9.225
52W High
$28.435
Market data snapshot near publication time

summarizeSummary

Perrigo shareholders approved a new 2026 Long-Term Incentive Plan, authorizing a substantial number of shares for future equity awards, and renewed the Board's authority to issue shares, alongside other routine annual meeting proposals.


check_boxKey Events

  • New Long-Term Incentive Plan Approved

    Shareholders approved the 2026 Long-Term Incentive Plan, which replaces the 2019 plan and authorizes 7,265,000 new shares for future equity awards, plus any unissued or forfeited shares from the prior plan. This represents over 5% potential dilution based on current outstanding shares.

  • Board Authority to Issue Shares Renewed

    Shareholders renewed the Board's authority to issue shares under Irish law and to opt-out of statutory pre-emption rights, providing flexibility for future capital raises or share issuances.

  • Directors Re-elected

    All nine nominated directors were re-elected to hold office until the 2027 Annual General Meeting of Shareholders.

  • Executive Compensation and Auditor Ratified

    Shareholders provided advisory approval for executive compensation and ratified the appointment of Ernst & Young LLP as the independent auditor for 2026.


auto_awesomeAnalysis

The approval of the 2026 Long-Term Incentive Plan is a key corporate governance event, enabling Perrigo to continue using equity for employee incentives. The plan authorizes a significant number of shares, representing over 5% of the current outstanding shares, which introduces substantial potential dilution for existing shareholders over time. This comes as the company navigates financial challenges, including a recent net loss and goodwill impairment, making talent retention critical. Additionally, shareholders renewed the Board's authority to issue shares and opt-out of pre-emption rights, providing flexibility for future capital activities. While these authorizations are not immediate share issuances, they signal potential future dilution. The re-election of directors and ratification of executive compensation and auditors were routine matters.

At the time of this filing, PRGO was trading at $11.64 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $9.23 to $28.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed PRGO - Latest Insights

PRGO
May 06, 2026, 4:14 PM EDT
Filing Type: 10-Q
Importance Score:
9
PRGO
May 06, 2026, 6:33 AM EDT
Filing Type: 8-K
Importance Score:
8
PRGO
May 06, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
PRGO
May 05, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
PRGO
Apr 30, 2026, 4:43 PM EDT
Filing Type: 8-K
Importance Score:
8
PRGO
Apr 22, 2026, 4:47 PM EDT
Filing Type: 8-K
Importance Score:
7
PRGO
Mar 23, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
8
PRGO
Mar 20, 2026, 11:33 AM EDT
Filing Type: DEF 14A
Importance Score:
8
PRGO
Feb 26, 2026, 1:34 PM EST
Filing Type: 10-K
Importance Score:
9
PRGO
Feb 26, 2026, 6:38 AM EST
Filing Type: 8-K
Importance Score:
9